<?xml version="1.0" encoding="utf-8" ?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>ORAMED PHARMACEUTICALS RSS Feed | Nachrichten - www.finanzen.net</title><description>www.finanzen.net bietet Finanznachrichten zum weltweiten Börsengeschehen</description><category>Finanzen</category><link>https://www.finanzen.net</link><language>de-de</language><copyright>finanzen.net GmbH</copyright><lastBuildDate>Mon, 06 Apr 2026 01:43:10 +0200</lastBuildDate><atom:link href="https://www.finanzen.net/rss/oramed%5Fpharmaceuticals%2Drss%2Dfeed" rel="self" type="application/rss+xml"/><image><url>https://images.finanzen.net/images/finanzen_net_neu.gif</url><title>ORAMED PHARMACEUTICALS RSS Feed | Nachrichten - www.finanzen.net</title><link>https://www.finanzen.net</link></image><item><title>Oramed Pharmaceuticals verkündete Quartalsergebnis zum jüngsten Jahresviertel</title><pubDate>Sat, 28 Mar 2026 06:35:07 +0100</pubDate><link>https://www.finanzen.net/nachricht/aktien/oramed-pharmaceuticals-verkuendete-quartalsergebnis-zum-juengsten-jahresviertel-15582171</link><description><![CDATA[<p><a href="https://www.finanzen.net/aktien/oramed_pharmaceuticals-aktie">Oramed Pharmaceuticals</a> äußerte sich am 26.03.2026 zu den Geschäftsergebnissen des am 31.12.2025 abgelaufenen Quartals.Es wurde ein Gewinn je Aktie von 0,24 USD ausgewiesen. Im Vorjahresquartal war ein  ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/oramed-pharmaceuticals-verkuendete-quartalsergebnis-zum-juengsten-jahresviertel-15582171</guid></item><item><title>Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments</title><pubDate>Wed, 07 Jan 2026 14:55:00 +0100</pubDate><link>https://www.finanzen.net/nachricht/aktien/oramed-receives-18-million-payment-from-scilex-holdings-bringing-current-returns-to-118-million-board-approves-dividend-payments-15398890</link><description><![CDATA[<p><p class="prntac" xmlns="http://www.w3.org/1999/xhtml"><i>Payment Closes Out Option Agreement Obligations; Oramed Retains <span class="xn-money">$39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty Interest</i><p xmlns="http://www.w3.org/1999/xhtml"><span  ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/oramed-receives-18-million-payment-from-scilex-holdings-bringing-current-returns-to-118-million-board-approves-dividend-payments-15398890</guid></item><item><title>Oramed Reports Fiscal Third Quarter 2025 Financial Results</title><pubDate>Mon, 17 Nov 2025 14:56:00 +0100</pubDate><link>https://www.finanzen.net/nachricht/aktien/oramed-reports-fiscal-third-quarter-2025-financial-results-15284376</link><description><![CDATA[<p><p xmlns="http://www.w3.org/1999/xhtml"><b><i>Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to <span class="xn-money">$220.5 Million</i></b><p xmlns="http://www.w3.org/1999/xhtml"><span class="legendSpanClass"><span  ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/oramed-reports-fiscal-third-quarter-2025-financial-results-15284376</guid></item><item><title>ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS</title><pubDate>Mon, 17 Nov 2025 14:50:00 +0100</pubDate><link>https://www.finanzen.net/nachricht/aktien/oramed-pharmaceuticals-inc-declares-dividend-distribution-of-common-stock-purchase-rights-15284359</link><description><![CDATA[<p><p xmlns="http://www.w3.org/1999/xhtml"><span class="legendSpanClass"><span class="xn-location">NEW YORK, <span class="legendSpanClass"><span class="xn-chron">Nov. 17, 2025 /PRNewswire/ -- The Board of Directors of Oramed Pharmaceuticals Inc. (the "Company")  ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/oramed-pharmaceuticals-inc-declares-dividend-distribution-of-common-stock-purchase-rights-15284359</guid></item><item><title>Oramed Pharmaceuticals mit Zahlen zum abgelaufenen Quartal</title><pubDate>Sat, 15 Nov 2025 06:35:06 +0100</pubDate><link>https://www.finanzen.net/nachricht/aktien/oramed-pharmaceuticals-mit-zahlen-zum-abgelaufenen-quartal-15278486</link><description><![CDATA[<p><a href="https://www.finanzen.net/aktien/oramed_pharmaceuticals-aktie">Oramed Pharmaceuticals</a> präsentierte in der am 13.11.2025 stattfindenden Finanzkonferenz das Zahlenwerk zum jüngsten Quartal, welches am 30.09.2025 endete.Der Gewinn je Aktie belief sich auf 1,13 USD.  ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/oramed-pharmaceuticals-mit-zahlen-zum-abgelaufenen-quartal-15278486</guid></item><item><title>Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives</title><pubDate>Thu, 23 Oct 2025 14:55:00 +0200</pubDate><link>https://www.finanzen.net/nachricht/aktien/oramed-releases-letter-to-shareholders-highlighting-developments-in-its-oral-insulin-program-significant-investment-appreciation-and-upcoming-growth-initiatives-15111096</link><description><![CDATA[<p><ul type="disc" xmlns="http://www.w3.org/1999/xhtml"><li><i>Oramed Advancing Oral Insulin Program Independently; Announces Launch of New U.S. Trial </i></li><li><i>Diversified Investment Portfolio Delivers Strong Returns </i></li><li><i>Company </i><i>Accelerating  ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/oramed-releases-letter-to-shareholders-highlighting-developments-in-its-oral-insulin-program-significant-investment-appreciation-and-upcoming-growth-initiatives-15111096</guid></item></channel></rss>
